---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-001488"
form_type: "8-K"
ticker: "PRPH"
cik: "0000868278"
company_name: "ProPhase Labs, Inc."
filed_at: "2025-03-31T23:59:59+00:00"
generated_at: "2026-05-24T02:42:55.607154+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# ProPhase Labs reports FY2024 net loss of $53.4M; revenue down 81% to $6.8M

## Summary
- Net revenue fell 80.6% to $6.8M from $35.0M, driven by near-zero COVID-19 testing volumes.
- Net loss widened to $53.4M ($2.61/share) vs $16.8M ($0.98/share) in FY2023; gross loss of $0.2M.
- Manufacturing division sold for ~$23M in Jan 2025; employee count reduced from 96 to 28.
- Cash and equivalents $0.7M at Dec 31, 2024, down from $1.6M; working capital deficit of $1.5M.
- Company plans cash-pay launch of BE-Smart esophageal test; evaluating sale of Nebula Genomics.

## SEC filing metadata
- accession: 0001641172-25-001488
- form_type: 8-K
- ticker: PRPH
- cik: 0000868278
- company_name: ProPhase Labs, Inc.
- filed_at: 2025-03-31T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/868278/000164117225001488/0001641172-25-001488-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/868278/000164117225001488/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-001488
- JSON: https://secwatch.observer/filing/0001641172-25-001488.json
- Plain text: https://secwatch.observer/filing/0001641172-25-001488.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.